In vitro Activity of Rufloxacin against Listeria monocytogenes, Legionella pneumophila, and Chlamydia trachomatis

Chemotherapy ◽  
1994 ◽  
Vol 40 (2) ◽  
pp. 104-108 ◽  
Author(s):  
P.M. Furneri ◽  
M. Bazzano ◽  
L. Campo ◽  
M. Cesana ◽  
G. Tempera
2005 ◽  
Vol 49 (3) ◽  
pp. 1201-1202 ◽  
Author(s):  
Manuela Donati ◽  
Korinne Di Leo ◽  
Monica Benincasa ◽  
Francesca Cavrini ◽  
Silvia Accardo ◽  
...  

ABSTRACT The in vitro activity of six cathelicidin peptides against 25 strains of Chlamydia was investigated. SMAP-29 proved to be the most active peptide, reducing the inclusion numbers of all 10 strains of Chlamydia trachomatis tested by ≥50% at 10 μg/ml. This peptide was also active against C. pneumoniae and C. felis.


1999 ◽  
Vol 44 (5) ◽  
pp. 693-695 ◽  
Author(s):  
A. Tsakris ◽  
S. Alexiou-Daniel ◽  
E. Souliou ◽  
A. Antoniadis

2004 ◽  
Vol 48 (5) ◽  
pp. 1885-1886 ◽  
Author(s):  
S. A. Kohlhoff ◽  
P. M. Roblin ◽  
T. Reznik ◽  
S. Hawser ◽  
K. Islam ◽  
...  

ABSTRACT The in vitro activities of iclaprim, a novel dihydrofolate reductase inhibitor, azithromycin, and levofloxacin were tested against 10 strains of Chlamydia trachomatis and 10 isolates of Chlamydia pneumoniae. For C. trachomatis and C. pneumoniae, the iclaprim MIC and minimal bactericidal concentration at which 90% of isolates were inhibited (MIC90 and MBC90) were 0.5 μg/ml, compared to an azithromycin MIC90 and MBC90 of 0.125 μg/ml and levofloxacin MIC90s and MBC90s of 1 μg/ml for C. trachomatis and 0.5 μg/ml for C. pneumoniae.


1987 ◽  
Vol 14 (3) ◽  
pp. 165-173 ◽  
Author(s):  
STEPHEN T. KNIGHT ◽  
SARA H. LEE ◽  
CAROLYN H. DAVIS ◽  
DAVlD R. MOORMAN ◽  
RICHARD L. HODINKA ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document